Want to join the conversation?
In 3Q15, upon regulatory approval for Strensiq and Kanuma, $587MM acquired IPR&D assets associated with Strensiq and $4.12Bil of acquired IPR&D assets associated with Kanuma were reclassified from acquired IPR&D to purchased technology. $ALXN has supply agreements with Lonza through 2028 for manufacture of Soliris and Strensiq.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.